| Citation | Alastair Compston has developed the anti-CD52 humanised monoclonal antibody Campath-1H (Alemtuzumab) as a highly effective treatment for early multiple sclerosis. With Herman Waldmann, he formulated the concept of lymphocyte depletion and immune reconstitution as a treatment for multiple sclerosis. He led clinical trials culminating in European and US approvals for Alemtuzumab, and licences in more than 50 countries. It is difficult to exaggerate the importance of this work, taken from concept to drug licence, that transforms the outlook for patients threatened with neurological disability; and which has made a major clinical and commercial impact on the practice of neurology. |